UK life sciences

Patients

Houses of Parliament - a Labour government

Labour, the NHS, and life sciences: Partnerships and people

The United Kingdom this morning woke to landslide poll results: Labour is in on just 34% of the vote following the worst Conservative defeat in the party’s history.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

R&D

evolution of clinical research in the UK

The evolution of clinical research: Embracing new delivery m...

The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin

Market Access

Unlocking superpower status: The crucial role of space in sc...

There has been a lot of hype around the government's plan to

R&D

Sanofi asks ‘What If?’: Why the ‘big questions’ must be aske...

At the Royal College of Physicians on Thursday 27th July, Sanofi held an event focused on the state of UK life sciences and what can be done at this critical moment in time.

R&D

Focusing on predictability and execution in digital trials

Recently attending the Veeva R&D and Quality Summit in Madrid, pharmaphorum web editor Nicole Raleigh sat down with Veeva’s president of Europe, Chris Moore.

Market Access

ABPI Annual Conference 2023 – patients, partnerships, and po...

Attending this year’s Association of British Pharmaceutical Industry (ABPI) Conference in London on Thursday 27th April, it quickly became clear that the day would be a notable one – not ju